(4-fluoro-3-isopropylphenyl)methanamine | 1112179-28-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-fluoro-3-isopropylphenyl)methanamine
• 英文别名: (4-fluoro-3-propan-2-ylphenyl)methanamine
• CAS: 1112179-28-8
• 化学式: C₁₀H₁₄FN
• 分子量: 167.226
• InChiKey: AIYMDQHZXUSGRO-UHFFFAOYSA-N

物化性质

• 沸点：
  222℃
• 密度：
  1.021
• 闪点：
  98℃

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-fluoro-3-isopropylphenyl)methanamine 、 methyl rac-6-(2-(((2S*,5R*)-5-hydroxymethyl-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxylate 以 N,N-二甲基乙酰胺 为溶剂， 反应 18.0h， 以35%的产率得到rac-N-(4-fluoro-3-isopropyl-benzyl)-6-[2-((2S*,5R*)-5-hydroxymethyl-[1,4]dioxan-2-ylmethyl)-2H-tetrazol-5-yl]-2-methyl-pyrimidine-4-carboxamide
  参考文献：
  名称：

  [EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS
  [FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION PHARMACEUTIQUE ET LEURS COMPOSITIONS

  摘要：

  公开号：

  WO2009016498A8

文献信息

• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DU TNF ALPHA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017023905A1

  公开（公告）日：2017-02-09

  Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is -(CR7R7)m-; L2 is -(CR7R7)n-; and X, Z, R1, R2, R3, R4, R5,and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  披露了公式(I)化合物或其盐，其中：A是CR1或N；B是CR3或N；D是CR4或N；L1是-(CR7R7)m-；L2是-(CR7R7)n-；X，Z，R1，R2，R3，R4，R5和R6都在此定义。还披露了将此类化合物用作调节TNFα的调节剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。
• QUINOLINE COMPOUNDS AND METHODS OF USE
  申请人：Gaudino John

  公开号：US20110053931A1

  公开（公告）日：2011-03-03

  Compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物、代谢物、盐和药学上可接受的前药，用于抑制受体酪氨酸激酶并治疗由此介导的过度增殖性疾病。本文揭示了使用式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• Tricyclic Gyrase inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10865216B2

  公开（公告）日：2020-12-15

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文公开了具有式 I 结构的化合物及其药学上适用的盐、酯和原药，它们可作为抗菌有效的三环回旋酶抑制剂。此外，本文还公开了三环回旋酶抑制剂化合物的种类。 还考虑了相关的药物组合物、用途和化合物的制造方法。
• Tricyclic gyrase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10858360B2

  公开（公告）日：2020-12-08

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文公开了具有式 I 结构的化合物及其药学上适用的盐、酯和原药，它们可作为抗菌有效的三环回旋酶抑制剂。 还考虑了相关的药物组合物、用途和化合物的制造方法。
• PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS
  申请人：Pfizer Inc.

  公开号：EP2185537A1

  公开（公告）日：2010-05-19